Circulating human mammary epithelial antigens in breast cancer - PubMed (original) (raw)

Comparative Study

Circulating human mammary epithelial antigens in breast cancer

R L Ceriani et al. Proc Natl Acad Sci U S A. 1982 Sep.

Abstract

Heterologous specific antisera against human mammary epithelial antigens (HME-Ags), which are present in the human milk fat globule membrane and breast epithelial cells, were used in a solid-phase radioimmunoassay to determine the presence of these antigens in the sera of patients with disseminated cancer of the breast and other organs. Breast cancer patients carry high levels of HME-Ags in their circulation, while patients with disseminated nonbreast cancer, as well as normal female controls, do not. A similar release of HME-Ags in the circulation was shown by us in a model system. To further corroborate these findings, a three-step procedure for the extraction and identification of HME-Ags from the sera was devised. In this analytical procedure, circulating HME-Ags are recovered on a solid phase carrying their corresponding antibody (anti-HME) and radioiodinated in situ. Later, the labeled HME-Ags are released from the solid phase and characterized by NaDodSO4 gel electrophoresis. With this procedure, HME-Ags were isolated from sera of breast cancer patients but not from sera of nonbreast cancer patients or of normal female controls. The extracted HME-Ags had molecular masses of 150,000, 70,000, and 46,000 daltons. To further support these findings, a monoclonal antibody, BLMRL-HMFG-Mc3, directed to the 46,000-dalton HME-Ag was also used to extract its corresponding antigen from sera. Breast cancer patient sera contained such antigen while the sera of the other patients and controls did not. This highly sensitive methodology offers a specific approach to breast cancer diagnosis as well as further insight into the nature of circulating antigens with a view to increasing our understanding of breast cancer biology.

PubMed Disclaimer

Cited by

Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice.
Carmon L, Bobilev-Priel I, Brenner B, Bobilev D, Paz A, Bar-Haim E, Tirosh B, Klein T, Fridkin M, Lemonnier F, Tzehoval E, Eisenbach L. Carmon L, et al. J Clin Invest. 2002 Aug;110(4):453-62. doi: 10.1172/JCI14071. J Clin Invest. 2002. PMID: 12189239 Free PMC article.
The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer.
Berry N, Jones DB, Smallwood J, Taylor I, Kirkham N, Taylor-Papadimitriou J. Berry N, et al. Br J Cancer. 1985 Feb;51(2):179-86. doi: 10.1038/bjc.1985.27. Br J Cancer. 1985. PMID: 2578285 Free PMC article.
Diagnostic ability of different human milk fat globule antigens in breast cancer.
Ceriani RL, Blank EW, Rosenbaum EH, Ben Zeev D, Lowitz RS, Johansen L, Trujillo T. Ceriani RL, et al. Breast Cancer Res Treat. 1990 May;15(3):161-74. doi: 10.1007/BF01806353. Breast Cancer Res Treat. 1990. PMID: 2372570
Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.
Wong JH, Aguero B, Gupta RK, Morton DL. Wong JH, et al. Cancer Immunol Immunother. 1988;27(2):142-6. doi: 10.1007/BF00200019. Cancer Immunol Immunother. 1988. PMID: 3046746 Free PMC article.

References

1. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
1. Proc Soc Exp Biol Med. 1971 Apr;136(4):1261-4 - PubMed
1. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3537-41 - PubMed
1. J Natl Cancer Inst. 1975 Sep;55(3):555-60 - PubMed
1. Science. 1975 Oct 17;190(4211):276-8 - PubMed

Circulating human mammary epithelial antigens in breast cancer - PubMed (original) (raw)